Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer

被引:1
|
作者
Linde, Caroline [1 ]
Chien, Yu-Ting [1 ]
Chen, Zhiqian [1 ]
Mu, Qingxin [1 ]
机构
[1] Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
美国国家卫生研究院;
关键词
nanoparticles; triple negative breast cancer; PD-1/PD-L1; pathway; combination therapy; tumor microenvironment; CHEMOTHERAPY; PHARMACOKINETICS; IMMUNOTHERAPY;
D O I
10.3389/fonc.2024.1393492
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer with triple-negative subtype (TNBC) presents significant challenges with limited treatment options and a poorer prognosis than others. While PD-1/PD-L1 checkpoint inhibitors have shown promise, their efficacy in TNBC remains constrained. In recent years, nanoparticle (NP) technologies offer a novel approach to enhance cancer therapy by optimizing the tumor microenvironment and augmenting chemo- and immunotherapy effects in various preclinical and clinical settings. This review discusses recent investigations in NP strategies for improving PD-1/PD-L1 blockade-based combination therapy for TNBC. Those include single or multi-therapeutic NPs designed to enhance immunogenicity of the tumor, induce immunogenic cell death, and target immunosuppressive elements within the tumor microenvironment. The investigations also include NPs co-loaded with PD-L1 inhibitors and other therapeutic agents, leveraging targeted delivery and synergistic effects to maximize efficacy while minimizing systemic toxicity. Overall, NP approaches represent a promising avenue for enhancing PD-1/PD-L1 checkpoint blockade-based combination therapy in TNBC and encourage further developmental studies.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
    Yang, Tinglin
    Li, Wenhui
    Huang, Tao
    Zhou, Jun
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
  • [2] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 818 - 830
  • [3] Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer
    Nakhjavani, Maryam
    Shigdar, Sarah
    PHARMACOLOGICAL RESEARCH, 2022, 175
  • [4] Combination therapy with PD-1 or PD-L1 inhibitors for cancer
    Hidetoshi Hayashi
    Kazuhiko Nakagawa
    International Journal of Clinical Oncology, 2020, 25 : 818 - 830
  • [5] PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression
    Alkaabi, Duaa
    Arafat, Kholoud
    Sulaiman, Shahrazad
    Al-Azawi, Aya Mudhafar
    Attoub, Samir
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (07)
  • [6] Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
    Hongshu Li
    Ying Chang
    Tiefeng Jin
    Meihua Zhang
    Cancer Cell International, 25 (1)
  • [7] Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
    Chen, Xingyu
    Feng, Lixiang
    Huang, Yujing
    Wu, Yi
    Xie, Na
    CANCERS, 2023, 15 (01)
  • [8] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [9] Addition of PD-1/PD-L1 inhibitors to chemotherapy for triple-negative breast cancer: a meta-analysis
    Yang, Juan
    Liu, Chen
    Guo, Yaru
    Guo, Wenwen
    Wu, Xiaojin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [10] Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis
    Zhang, Meilin
    Song, Jian
    Yang, Hongguang
    Jin, Feng
    Zheng, Ang
    ACTA ONCOLOGICA, 2022, 61 (09) : 1105 - 1115